Sunny
Sunny is an MD candidate at Harvard Medical School. Previously, she spent seven years researching neurodegenerative diseases. Notably, she was a part of a group studying cell replacement therapy for Parkinson’s disease which, in 2021, entered a Phase I clinical trial for patients with advanced Parkinson's disease
Ash
Ash received his MA in Economics from Columbia University. He graduated with a degree in Electrical Engineering and Econometrics from the University of Alabama at Birmingham (summa cum laude, Tau Beta Pi).
Elizabeth
Elizabeth is an MD/PhD student at NYU School of Medicine's Medical Scientist Training Program. She holds a BA in Biology with a minor in English from Hunter College.
Ameen
Ameen is an MD candidate at Harvard. A Rhodes Scholar and Goldwater Scholarship recipient, he holds a Master's in Public Policy (Oxford) and a Bachelor's in Neuroscience and Translational Research (University of Alabama).